NASA has confirmed that the agency, in coordination with SpaceX, is targeting no earlier than 5 p.m. Eastern Time (2200 GMT) on Wednesday, January 14, for the undocking of the SpaceX Crew-11 mission from the International Space Station (ISS). The planned departure remains dependent on favorable weather conditions, which are a key factor in ensuring a safe return to Earth for the astronauts aboard the mission.
The announcement comes amid heightened attention after NASA disclosed earlier this week that it was considering an early return of the ISS crew due to what the agency described as a “medical concern” involving one of the astronauts. While NASA has not released specific details regarding the nature of the medical issue, officials emphasized that the health and safety of the crew remain the top priority and that contingency plans are a routine part of human spaceflight operations.
The SpaceX Crew-11 mission is part of NASA’s Commercial Crew Program, which relies on SpaceX’s Crew Dragon spacecraft to transport astronauts to and from the ISS. The mission has been docked at the orbiting laboratory while the crew carried out a range of scientific experiments, technology demonstrations, and station maintenance tasks critical to ongoing space research.
NASA stated that mission managers are continuing to closely monitor the astronaut’s condition, overall crew readiness, spacecraft performance, and weather patterns at the designated splashdown zones. Any changes to the undocking timeline will be communicated as more information becomes available.
The potential early undocking highlights the flexibility built into modern space missions, allowing agencies like NASA and partners such as SpaceX to respond quickly to unforeseen situations. As the target date approaches, space enthusiasts and industry observers will be watching closely for updates on the Crew-11 return, the astronaut’s health status, and how the mission concludes.
For now, NASA maintains that the January 14 undocking window remains the earliest opportunity, pending final assessments, underscoring the careful balance between mission objectives and astronaut well-being in human spaceflight.


Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Elliott Investment Management Takes Multibillion-Dollar Stake in Synopsys 



